|8.26||+0.07 / +0.85%|
As of 3:59pm ET
|8.16||-0.095 / -1.15%|
The 6 analysts offering 12-month price forecasts for Regulus Therapeutics Inc have a median target of 28.50, with a high estimate of 41.00 and a low estimate of 16.00. The median estimate represents a +245.04% increase from the last price of 8.26.
The current consensus among 7 polled investment analysts is to Buy stock in Regulus Therapeutics Inc. This rating has held steady since July, when it was unchanged from a Move your mouse over past
months for detail
Move your mouse over a quarter or year to see how estimates have changed over time.